Buscopan (Hyoscine Butylbromide) Should Not Be Used at 20 Weeks Gestation
Buscopan (hyoscine butylbromide) lacks adequate safety data in pregnancy and should be avoided at 5 months antenatal (20 weeks gestation). The FDA drug label classifies it as Pregnancy Category B, meaning animal studies show no harm but adequate human studies are lacking, and it should only be used "if clearly needed" 1.
Why This Recommendation
Limited Human Safety Data
The critical issue is the absence of well-controlled human studies during pregnancy. While animal reproduction studies at 30 times the human dose showed no fertility impairment or fetal damage in rats and rabbits, animal studies are not always predictive of human response 1.
Concerning Experimental Evidence
Recent research raises red flags about Buscopan's effects on developing nervous systems:
- A 2021 chick embryo study demonstrated that Buscopan adversely affected early nervous system and neural tube development in a dose-dependent manner, with decreased cell division and proliferation activity 2
- At 20 weeks gestation, critical fetal neurological development is ongoing, making this particularly concerning
Lack of Established Obstetric Indication
The evidence provided shows Buscopan is being studied for labor augmentation (to shorten labor duration), not for use during mid-pregnancy 3, 4. The WHO and Cochrane reviews have advised against antispasmodics for labor due to insufficient rigorous evidence 3. Using it at 20 weeks would be:
- Off-label for any pregnancy-related indication
- Outside the studied gestational age range
- Without established benefit for maternal or fetal outcomes
Clinical Context
If Buscopan is being considered for gastrointestinal cramping or bladder spasms at 20 weeks gestation, safer alternatives exist:
For constipation/GI symptoms:
- Dietary fiber (30 g/day)
- Bulk-forming agents (psyllium, methylcellulose) - safe due to lack of systemic absorption
- Osmotic laxatives (polyethylene glycol, lactulose) 5
For bladder pain syndrome in pregnancy:
- Oral amitriptyline (lowest risk oral treatment)
- Intravesical heparin (safest intravesical treatment - unlikely to cross placenta) 6
Key Pitfall to Avoid
Do not assume that "Pregnancy Category B" means the drug is safe. Category B specifically indicates insufficient human data, which is fundamentally different from proven safety. The FDA label explicitly states it "should be used during pregnancy only if clearly needed" 1, and at 20 weeks gestation with safer alternatives available, this threshold is not met.